Investigational drug · Phase 3
DR10624
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Severe Hypertriglyceridemia, Hypertriglyceridemia, Severe Hypertriglyceridemia (sHTG).
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
7
Any phase or sponsor naming "DR10624"
First trial start
2024
Aug 1, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DR10624", any sponsor or status.
Conditions studied
As listed on its trial records.
- Severe Hypertriglyceridemia
- Hypertriglyceridemia
- Severe Hypertriglyceridemia (sHTG)
- MASLD
Approved drugs for the same conditions: High triglycerides · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "DR10624" as an intervention, largest first.
- A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe HypertriglyceridemiaPivotal-lookingNot yet recruiting
Zhejiang Doer Biologics Co., Ltd.Industry
NCT07693777 · 480 participants (planned) · Start Aug 17, 2026 · Primary completion Feb 14, 2029
Drug: DR10624 Injection · For: Severe Hypertriglyceridemia (sHTG); Hypertriglyceridemia
Sites: Shanghai, China
- A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe HypertriglyceridemiaPivotal-lookingNot yet recruiting
Zhejiang Doer Biologics Co., Ltd.Industry
NCT07680829 · 378 participants (planned) · Start Aug 2026 · Primary completion Jun 2030
Drug: DR10624 Subcutaneous Injection; Icosapent Ethyl Oral Capsule and 1 more · For: Severe Hypertriglyceridemia
Sites: Beijing, China · 2 sites in all
- A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney DiseasePivotal-lookingNot yet recruiting
Zhejiang Doer Biologics Co., Ltd.Industry
NCT07848880 · 315 participants (planned) · Start Oct 2026 · Primary completion Apr 2028
Drug: DR10624 Injection; Placebo · For: Hypertriglyceridemia
Sites: Beijing, China · 2 sites in all
- A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624Pivotal-lookingCompleted
Zhejiang Doer Biologics Co., Ltd.Industry
NCT05378893 · 153 participants · Start Jun 22, 2022 · Primary completion Oct 10, 2024
Drug: DR10624 for injection; Placebo · For: Healthy, Obesity, Metabolically
Sites: Christchurch, New Zealand
- Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD SubjectsPivotal-lookingActive, not recruiting
Zhejiang Doer Biologics Co., Ltd.Industry
NCT07024212 · 110 participants (planned) · Start Apr 22, 2025 · Primary completion Jun 18, 2026
Drug: DR10624 Injection; Placebo · For: MASLD
Sites: Hangzhou, China; Changchun, China; Nanjing, China · 4 sites in all
Zhejiang Doer Biologics Co., Ltd.Industry
NCT06555640 · 79 participants · Start Aug 1, 2024 · Primary completion Jun 30, 2025
Drug: DR10624 Injection; Placebo · For: Severe Hypertriglyceridemia
Sites: Baoding, China; Baotou, China; Beijing, China · 35 sites in all
- A Trial to Evaluate the Efficacy and Safety of DR10624 in Patients With Hypertriglyceridemia and Carotid Atherosclerotic PlaqueEnrolling by invitation
Junbo GeAcademic, hospital or other
NCT07050134 · 40 participants (planned) · Start Jul 1, 2025 · Primary completion Dec 31, 2026
Drug: DR10624 Injection;; DR10624 Injection Placebo (referred to as placebo) · For: Hypertriglyceridemia; Carotid Atherosclerotic Plaques
Sites: Hefei, China; Suzhou, China; Shanghai, China · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Analysis of drug development risks for metabolic dysfunction-associated steatotic liver disease from a sustainable accounting perspective.
Liu X, Mirza M · Cost Eff Resour Alloc 2026
- Terminus-specific antibody development and bioanalytical assay validation to quantify active DR10624 in pharmacokinetic studies.
Zhou Z, Cao K, Yao G, et al. · Front Pharmacol 2026
- Highlights of Cardiovascular Disease Prevention Studies Presented at the 2025 American Heart Association Scientific Sessions.
Abdul Jabbar AB, Naeem U, Zulfiqar K, et al. · Curr Atheroscler Rep 2026
Also in development for Severe Hypertriglyceridemia
- PegozaferminBIO89-100Phase 33 trials
Roche (Genentech) · Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Severe Hypertriglyceridemia
- ION775Phase 21 trial
Ionis Pharmaceuticals · Hypertriglyceridemia, Severe Hypertriglyceridemia
- SolbinsiranLY3561774Phase 21 trial
Eli Lilly · Severe Hypertriglyceridemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.